DUBLIN, Ireland – Perrigo Co. has been cleared by the Food and Drug Administration to market repaglinide tablets in strengths of 1 mg and 2 mg.
The company said Friday that its product is a generic equivalent of Novo Nordisk's Prandin tablets (repaglinide).
Perrigo has begun shipping the new Prandin generic product. The company previously launched the 0.5-mg strength of repaglinide tablets last year.
Repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The medication has annual sales of approximately $250 million, according to data from Symphony Health Solutions reported by Perrigo.